Developing a sentence level fairness metric using word embeddings.

Fairness is a principal social value that is observable in civilisations around the world. Yet, a fairness metric for digital texts that describe even a simple social interaction, e.g., 'The boy hurt the girl' has not been developed. We address this by employing word embeddings that use factors found in a new social psychology literature review on the topic. We use these factors to build fairness vectors. These vectors are used as sentence level measures, whereby each dimension reflects a fairness component. The approach is employed to approximate human perceptions of fairness. The method leverages a pro-social bias within word embeddings, for which we obtain an F1 = 79.8 on a list of sentences using the Universal Sentence Encoder (USE). A second approach, using principal component analysis (PCA) and machine learning (ML), produces an F1 = 86.2. Repeating these tests using Sentence Bidirectional Encoder Representations from Transformers (SBERT) produces an F1 = 96.9 and F1 = 100 respectively. Improvements using subspace representations are further suggested. By proposing a first-principles approach, the paper contributes to the analysis of digital texts along an ethical dimension.

Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease.

Apolipoprotein E ɛ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ɛ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ɛ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ɛ4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age- and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ɛ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ɛ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.